Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Fineline Cube Jan 20, 2026
Company Deals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

Fineline Cube Jan 20, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

Fineline Cube Jan 20, 2026
Company Drug

AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly

Fineline Cube Jan 20, 2026
Company Deals

Recbio Partners with Biological E for HPV VaccineREC603’s India and Global Expansion

Fineline Cube Jul 1, 2025

China-based Jiangsu Recbio Technology Co., Ltd. (HKG: 2179) announced a licensing agreement with India-headquartered Biological...

Company Drug

Astellas Pharma’s Vyloy Gains First Prescriptions Across China for Gastric Cancer

Fineline Cube Jul 1, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) announced that the first prescriptions for Vyloy (zolbetuximab) in...

Others

Guangdong Announces First Batch of Approved Innovative Drugs and Medical Devices

Fineline Cube Jul 1, 2025

Departments including the Department of Industry and Information Technology, Health Commission, Healthcare Security Administration, and...

Company Drug

Santen’s Tapcom Administered to First Patient in GBA via Drug Access Policy

Fineline Cube Jul 1, 2025

Japan-based Santen Pharmaceutical Co., Ltd. announced that its novel glaucoma treatment, Tapcom (tafluprost/timolol maleate), has...

Company Deals

Zhaoke Ophthalmology Partners with Jamjoom Pharma for Cyclosporine Eye Gel Distribution in Middle East

Fineline Cube Jul 1, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced a partnership with Jamjoom Pharma, a leading Saudi...

Company Drug

Ascletis Faces Patent Challenge from CSPC Subsidiary Conjupro Bio

Fineline Cube Jul 1, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) this week disclosed that Conjupro Biotherapeutics, a subsidiary of...

Company Deals

Fosun Pharma Secures Licensing Deal for HCB101 SIRPα-Fc Fusion Protein

Fineline Cube Jul 1, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) has entered into a licensing...

Company Drug

Zai Lab’s Bemarituzumab Meets Phase III Endpoint in Gastric Cancer Trial

Fineline Cube Jul 1, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that its Phase III FORTITUDE-101...

Company Drug

Hengrui Pharmaceuticals’ Aihengping Gains NMPA Approval for Regional Analgesia

Fineline Cube Jul 1, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received marketing approval...

Company Drug

Avistone’s Vebreltinib Wins NMPA Approval for MET-Amplified NSCLC

Fineline Cube Jul 1, 2025

Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd. announced that its subsidiary Pearl Bio’s c-MET inhibitor vebreltinib...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for Aisuda in Severe Alopecia Areata

Fineline Cube Jul 1, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received additional indication approval from the...

Company Medical Device

MicroPort NeuroTech’s NUMEN Nest Gains FDA Marketing Approval

Fineline Cube Jul 1, 2025

China-based MicroPort NeuroTech Limited (HKG: 2172) announced that its NUMEN Nest, an enhanced version of...

Company Drug

BMS Secures FDA Approval for Updated Labels of Breyanzi and Abecma

Fineline Cube Jul 1, 2025

US major Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the US Food and Drug Administration...

Company Deals

GenScript Receives $213.8M Payment from LaNova for PD-1 Antibody License

Fineline Cube Jun 30, 2025

China-based GenScript Biotech Corporation (HKG: 1548) announced that it has received a payment of USD...

Company Drug

UCB’s Fenfluramine Shows Positive Results in Phase III GEMZ Study for CDKL5 Deficiency Disorder

Fineline Cube Jun 30, 2025

Belgium-based biopharma UCB (EBR: UCB) announced positive results from its Phase III GEMZ study, evaluating...

Company Deals

Sunshine Lake Pharma Lists on HKEX via Introduction Method

Fineline Cube Jun 30, 2025

China-based Sunshine Lake Pharma Co., Ltd. (HKG: 6887) has successfully listed on the Main Board...

Company Deals

MGI Tech Partners with Italy’s Negedia to Advance Genomic Sequencing and Spatial Transcriptomics

Fineline Cube Jun 30, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd. announced a collaboration with Italy’s Negedia to...

Policy / Regulatory

China Proposes Healthcare Security Law to Strengthen Medical Insurance System

Fineline Cube Jun 30, 2025

China’s National Healthcare Security Administration (NHSA) last week released the “Healthcare Security Law (draft proposal)”,...

Company Deals

QuantumPharm and Pfizer Expand Collaboration on Advanced Molecular Simulation Platform

Fineline Cube Jun 30, 2025

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228), has announced an expansion of its...

Company Deals

BlissBio Inc. Files for Hong Kong IPO to Advance Oncology-Focused ADC Pipeline

Fineline Cube Jun 30, 2025

Hangzhou-based oncology-focused clinical-stage biotech BlissBio Inc. has filed for an initial public offering (IPO) with...

Posts pagination

1 … 80 81 82 … 611

Recent updates

  • Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal
  • Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study
  • AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly
  • Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus
  • Grand Pharmaceutical Files TLX591-CDx PSMA Diagnostic for Prostate Cancer in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Company Drug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

Company Drug

AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly

Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.